In aggressive B cell lymphoma, characterised by a metabolic switch to fatty acid metabolism and high FATP1 activity, inhibiting FATP1 with arylpiperazine 5K leads to a decrease in the tumour burden and invasiveness [50] (Table 1). This evidence concerns the gene SLC27A1 and B-cell non-Hodgkin lymphoma.